Orexigen Therapeutics, Third Phase III Trial for Contrave to Treat Obesity

Oct 17, 2007 - Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, announced the initiation of the third trial in its Phase III clinical trial program for its lead product candidate Contrave™ as a treatment for obesity. The program includes a set of four Phase III trials evaluating a variety of obesity-related outcome measures... Orexigen Therapeutics' Press Release-

AstraZeneca, Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms

October 16, 2007 - The link between gastroesophageal reflux disease (GERD) and obesity has long been established, but healthcare professionals have had little guidance as to whether obese patients with GERD* should be treated differently than normal-weight patients with GERD. Two studies about obesity and its relationship to GERD were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting this week... AstraZeneca's Press Release-

Sound Health Solutions, Support for Microsoft HealthVault

Oct. 4, 2007 - Sound Health Solutions, Inc. today announced support for HealthVault, Microsoft Corporation's newly launched consumer-health platform that provides consumers with the ability to search, store and connect their health information, simplifying management of their health and wellness... Sound Health Solutions, Inc. offers highly successful, multi-disciplinary weight management programs designed by physicians.... Sound Health Solutions' Press Release-

GSK , OTC weight loss product In Europe

Tuesday 2 October 2007 - GlaxoSmithKline (GSK) announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agency for the Evaluation of Medicinal Products (EMEA)...Alli is the only FDA-approved weight-loss product available to consumers without a prescription, and it is the first clinically-proven over-the-counter product to be combined with a comprehensive support programme... GlaxoSmithKline's Press Release -

Nastech Pharmaceutical , Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity

Oct. 1 , 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint... Nastech Pharmaceutical's Press Release -